4.8 Article

Neutrophil-like Cell-Membrane-Coated Nanozyme Therapy for Ischemic Brain Damage and Long-Term Neurological Functional Recovery

Journal

ACS NANO
Volume 15, Issue 2, Pages 2263-2280

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsnano.0c07973

Keywords

biomimetic nanomedicine; brain microvascular endothelial cells; nanozymes; ischemic stroke; neurological repair; Prussian blue nanozyme

Funding

  1. National Natural Science Foundation of China [81801822, 21725502, 51961145403]
  2. National Key R&D Program of China [2018YFC0115200, 2017YFA0207303]
  3. Key Basic Research Program of Science and Technology Commission of Shanghai Municipality [20JC1411700, 19490713100, 20490710600, 20S31903700]
  4. Shanghai Sailing Program [18YF1419000]
  5. King Saud University, Riyadh, Saudi Arabia [RSP-2020/90]

Ask authors/readers for more resources

This study introduces a neutrophil-like cell-membrane-coated mesoporous Prussian blue nanozyme, which improves the delivery of the nanozyme to the damaged brain for noninvasive active-targeting therapy in ischemic stroke. The long-term therapeutic efficacy of this nanozyme in ischemic stroke is demonstrated, with a detailed mechanism involving uptake by microglia leading to beneficial effects like microglia polarization, reduced recruitment of neutrophils, decreased neuron apoptosis, and neural cell proliferation. This strategy offers an approach for nanozyme therapy in brain diseases.
Oxidative stress and a series of excessive inflammatory responses are major obstacles for neurological functional recovery after ischemic stroke. Effective noninvasive anti-inflammatory therapies are urgently needed. However, unsatisfactory therapeutic efficacy of current drugs and inadequate drug delivery to the damaged brain are major problems. Nanozymes with robust anti-inflammatory and antioxidative stress properties possess therapeutic possibility for ischemic stroke. However, insufficiency of nanozyme accumulation in the ischemic brain by noninvasive administration hindered their application. Herein, we report a neutrophil-like cell-membrane-coated mesoporous Prussian blue nanozyme (MPBzyme@NCM) to realize noninvasive active-targeting therapy for ischemic stroke by improving the delivery of a nanozyme to the damaged brain based on the innate connection between inflamed brain microvascular endothelial cells and neutrophils after stroke. The long-term in vivo therapeutic efficacy of MPBzyme@NCM for ischemic stroke was illustrated in detail after being delivered into the damaged brain and uptake by microglia. Moreover, the detailed mechanism of ischemic stroke therapy via MPBzyme@NCM uptake by microglia was further studied, including microglia polarization toward M2, reduced recruitment of neutrophils, decreased apoptosis of neurons, and proliferation of neural stem cells, neuronal precursors, and neurons. This strategy may provide an applicative perspective for nanozyme therapy in brain diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available